Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04893109 · ClinicalTrials.gov registry record · Phase 2
ATEMPT 2.0: Adjuvant T-DM1 vs TH
A Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT04893109 is a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 500 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT04893109, a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG trastuzumab-emtansine
- DRUG Trastuzumab SC
Study Locations (20)
Connecticut
- Smilow Cancer Hospital Care center at Derby - Derby
- Smilow Cancer Hospital Care center at Fairfield - Fairfield
- Smilow Cancer Hospital Care center at Glastonbury - Glastonbury
- Smilow Cancer Hospital Care center at Greenwich - Greenwich
- Smilow Cancer Hospital Care center at Guilford - Guilford
- Smilow Cancer Hospital Care center at St. Francis - Hartford
- Smilow Cancer Hospital Care center at Long Ridge - Long Ridge
- Yale Cancer Center at Yale University School of Medicine - New Haven
- Smilow Cancer Hospital Care center at North Haven - North Haven
- Stamford Hospital - Stamford
- Smilow Cancer Hospital Care center at Torrington - Torrington
- Smilow Cancer Hospital Care center at Trumbull - Trumbull
- Smilow Cancer Hospital Care center at Waterbury - Waterbury
- Smilow Cancer Hospital Care center at Waterford - Waterford
Florida
- Miami Cancer Institute/Baptist Hospital of Miami - Miami
- Miami Cancer Institute - Plantation (MCIP) - Plantation
Indiana
- Indiana University Health Joe & Shelly Schwarz Cancer Center - Carmel
- IU Health North Hospital - Carmel
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- The University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2028-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04893109
The ClinicalTrials.gov registry entry for NCT04893109 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.
NCT04893109 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Connecticut, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT04893109 about?
NCT04893109 is a clinical study titled "ATEMPT 2.0: Adjuvant T-DM1 vs TH". This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM...
What is the current status of trial NCT04893109?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2021-06-16. Estimated completion is 2028-05-01.
What conditions does trial NCT04893109 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer.
What interventions are being tested in trial NCT04893109?
The interventions under investigation include: Paclitaxel (DRUG), trastuzumab-emtansine (DRUG), Trastuzumab SC (DRUG).
Who is sponsoring clinical trial NCT04893109?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04893109 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.